By Phil Galewitz
Serenity Cole loved Christmas final month, enjoyable together with her household close to her St. Louis house, making crafts, and visiting buddies.
It was a distinction to how Cole, 18, spent a part of the 2024 vacation season. She was within the hospital — a frequent prevalence with sickle cell illness, a genetic situation that damages oxygen-carrying crimson blood cells and, for years, prompted debilitating ache in her legs and arms. Flare-ups usually would pressure her to cancel plans or miss college.
“With sickle cell, it hurts daily,” she stated. “It may be extra tolerable some days, however it’s a relentless factor.”
In Could, Cole accomplished a several-months-long gene remedy remedy that helps reprogram the physique’s stem cells to provide wholesome crimson blood cells.
She was one of many first Medicaid enrollees nationally to profit from a new fee mannequin during which the federal authorities negotiates the price of a cell or gene remedy with pharmaceutical firms on behalf of state Medicaid applications — after which holds them accountable for the remedy’s success.
Underneath the settlement, collaborating states will obtain “reductions and rebates” from the drugmakers if the therapies don’t work as promised, in line with the Facilities for Medicare & Medicaid Companies.
That’s a stark distinction from how Medicaid and different well being plans sometimes pay for medicine and therapies — the invoice often will get paid whatever the therapies’ advantages for sufferers. However CMS has not disclosed the total phrases of the contract, together with how a lot the drug firms will repay if the remedy doesn’t work.
The remedy Cole acquired gives a possible remedy for lots of the 100,000 primarily Black Individuals with sickle cell illness, which is estimated to shorten lifespans by greater than twenty years. However the remedy’s price presents a steep monetary problem for Medicaid, the joint state-federal authorities insurer for individuals with low incomes or disabilities. Medicaid covers roughly half of Individuals with the situation.
There are two gene therapies authorized by the Meals and Drug Administration in the marketplace, one costing $2.2 million per affected person and the opposite $3.1 million, with neither price together with the expense of the lengthy hospital keep.
The CMS program is among the uncommon well being initiatives began beneath President Joe Biden and continued in the course of the Trump administration. The Biden administration signed the deal with the 2 producers, Vertex Prescribed drugs and Bluebird Bio, in December 2024, opening the door for states to hitch voluntarily.
“This mannequin is a recreation changer,” Mehmet Oz, the CMS administrator, stated in a July assertion asserting that 33 states, Washington, D.C., and Puerto Rico had signed onto the initiative.
Requested for additional particulars on the contracts, Catherine Howden, a CMS spokesperson, stated in an announcement that the phrases of the agreements are “confidential and have solely been disclosed to state Medicaid companies.”
“Tackling the excessive price of medication in the US is a precedence of the present administration,” the assertion stated.
Citing confidentiality, two state Medicaid administrators and the 2 producers declined to disclose the monetary phrases of agreements.
New Therapies
The gene therapies, authorized in December 2023 for individuals 12 or older with sickle cell illness, supply an opportunity to dwell with out ache and problems, which may embody strokes and organ harm, and keep away from hospitalizations, emergency room visits, and different expensive care. The Biden administration estimated that sickle cell care already prices the well being system virtually $3 billion a yr.
With many dearer gene therapies on the horizon, the price of the sickle cell therapies presages monetary challenges for Medicaid. A whole bunch of cell and gene therapies are in scientific trials, and dozens may get federal approval within the subsequent few years.
If the sickle cell fee mannequin works, it can in all probability result in comparable preparations for different expensive therapies, notably for people who deal with uncommon illnesses, stated Sarah Emond, president and CEO of the Institute for Scientific and Financial Evaluate, an unbiased analysis institute that evaluates new medical therapies. “It is a worthy experiment,” she stated.
Organising fee for medicine based mostly on outcomes is smart when coping with excessive remedy prices and uncertainty about their long-term advantages, Emond stated.
“The juice needs to be well worth the squeeze,” she stated.
Scientific trials for the gene therapies included fewer than 100 sufferers and adopted them for under two years, leaving some state Medicaid officers anticipating reassurance they had been getting a great deal.
“What we care about is whether or not providers really enhance well being,” stated Djinge Lindsay, chief medical officer for the Maryland Division of Well being, which runs the state’s Medicaid program. Maryland is predicted to start accepting sufferers for the brand new sickle cell program this month.
Medicaid is already required to cowl virtually all FDA-approved medicine and therapies, however states have leeway to restrict entry by limiting which sufferers are eligible, organising a prolonged prior authorization course of, or requiring enrollees to first endure different therapies.
Whereas the gene remedy therapies are restricted to sure hospitals across the nation, state Medicaid officers say the federal mannequin means extra enrollees could have entry to the therapies with out different restrictions.
The producers additionally pay for fertility preservation corresponding to freezing reproductive cells, which could possibly be broken by chemotherapy in the course of the remedy. Sometimes, Medicaid doesn’t cowl that price, stated Margaret Scott, a principal with the consulting agency Avalere Well being.
Emond stated pharmaceutical firms had been within the federal deal as a result of it may result in faster acceptance of the remedy by Medicaid, in contrast with signing particular person contracts with every state.
This remedy can profit many sickle cell sufferers.
Edward Donnell Ivy, chief medical officer, Sickle Cell Illness Affiliation of America
States are interested in the federal program as a result of it gives assist monitoring sufferers along with negotiating the fee, she stated. Regardless of some secrecy across the new mannequin, Emond stated she expects a federally funded analysis will monitor the variety of sufferers in this system and their outcomes, permitting states to hunt rebates if the remedy just isn’t working.
This system may run for so long as 11 years, in line with CMS.
“This remedy can profit many sickle cell sufferers,” stated Edward Donnell Ivy, chief medical officer for the Sickle Cell Illness Affiliation of America.
He stated the federal mannequin will assist extra sufferers entry the remedy, although he famous utilization will rely partly on the restricted variety of hospitals that provide the multimonth remedy.
Hope for Sickle Cell Sufferers
Earlier than gene remedy, the one potential remedy for sickle cell sufferers was a bone marrow transplant — an possibility accessible solely to those that may discover a appropriate donor, about 25% of sufferers, Ivy stated. For others, lifelong administration contains drugs to scale back the illness’s results and handle ache, in addition to blood transfusions.
About 30 of Missouri’s 1,000 Medicaid enrollees with sickle cell illness will get the remedy within the first three years, stated Josh Moore, director of the state’s Medicaid program. To this point, fewer than 10 enrollees have acquired it for the reason that state started providing it in 2025, he stated.
Lower than a yr into the federal program, Moore stated it’s too early to inform its charge of success — outlined as an absence of painful episodes that result in a hospital go to. However he hopes it will likely be near the 90% charge seen over the course of a few years in scientific trials.
Moore stated the federal program based mostly on how properly the remedy works was most well-liked over slicing charges for a brand new and promising remedy, which might put the producers’ skill to develop new medicine in danger. “We need to be good stewards of taxpayer {dollars},” he stated.
He declined to touch upon how a lot the state could save from the association or disclose different particulars, corresponding to how a lot the drug firms may need to pay again, citing confidentiality of the contracts.
These days, Cole, who underwent gene remedy at St. Louis Youngsters’s Hospital, has been in a position to give attention to her hobbies — taking part in video video games, drawing, and portray – and incomes her highschool diploma.
She stated she was glad to get the remedy. The worst half was the chemotherapy, she stated, which left her unable to speak or eat — and entailed getting caught with needles.
She stated that her situation is “approach higher” and that she has had no ache episodes resulting in a hospital keep since finishing the remedy final spring. “I’m simply grateful I used to be in a position to get it.”
KFF Well being Information is a nationwide newsroom that produces in-depth journalism about well being points and is among the core working applications at KFF — an unbiased supply of well being coverage analysis, polling, and journalism. Study extra about KFF.
